Furthermore, extensive translational research investigating HER2 as a druggable target has resulted in the generation of multiple Food and Drug Administration (FDA)-approved therapeutics in multiple cancers including lung, gastrointestinal, and BC [8,28,29]. The gene discussed is ERBB2; the disease is breast cancer.